A gene called HER4 could hold the key to extending the lifespan of golden retrievers and potentially offer insights into human cancer studies.
- Golden retrievers, a beloved dog breed, face a high cancer mortality rate of up to 65%.
- Researchers from the University of California, Davis, sought to identify genes associated with longer life rather than cancer diagnosis.
- Their study revealed that a gene called HER4, linked to human cancers, extends a golden retriever's life by nearly two years.
- This discovery could have implications for humans, as dogs and humans share many similar cancer types.
- More than 300 golden retrievers participated in the study, and dogs with specific variants of HER4 lived significantly longer.
- The gene seemed to be more crucial for female dogs' longevity and may interact with hormones and environmental toxins.
- Further research aims to validate these findings and explore the gene's impact on expression and function.
mRNA-loaded vesicles for immunotherapy against glioblastoma
In a groundbreaking development, scientists are harnessing extracellular vesicles to supercharge immunotherapy for glioblastoma, potentially revolutionizing cancer treatment.
- Researchers at The University of Texas MD Anderson Cancer Center developed a novel method using extracellular vesicles to enhance immunotherapy responses in glioblastoma.
- They loaded mRNA into extracellular vesicles, small structures used to transport biomolecules, demonstrating their anti-tumor potential.
- mRNA therapies, recognised by the 2023 Nobel Prize, hold promise for cancer treatment, but delivery challenges exist.
- The team solved these issues by using a high-throughput system to produce mRNA-loaded vesicles from engineered cells.
- These vesicles were engineered to express specific proteins and loaded with mRNA encoding interferon-gamma, an immune-signalling protein.
- In preclinical models, this approach increased survival time and initial antitumor activity in glioblastoma.
- The method's adaptability allows it to be tailored for other tumor types by changing the targeted antibodies.
- Further preclinical work is underway to improve production methods and assess vesicle safety before clinical application.
Thank you for reading. I love writing these summaries. Hope you enjoy reading them. I would love to know what you think. Please let me know your thoughts!